In addition to a target engagement biomarker, there is also much interest in whether Rab10 phosphorylation comprises a disease progression biomarker, or especially a stratification biomarker that may identify sporadic PD patients with high levels of LRRK2 activity, who may be enrolled into LRRK2-targeted clinical trials. The gene discussed is RAB10; the disease is Parkinson disease.